Journal of Haehwa Medicine (혜화의학회지)

Research Institute of Korean Medicine (대전대학교 한의학연구소)
권호 표지

Case Report of Advanced Gastric Cancer Patient Treated with Hang-Am Plus

항암플러스 투여 후 호전된 진행성 위암 환자 증례보고

  • Park, Jae-Woo (East-West Cancer Center, Dunsan Oriental Hospital of Daejeon Universuty) ;
  • Yoo, Hwa-Seung (East-West Cancer Center, Dunsan Oriental Hospital of Daejeon Universuty) ;
  • Cho, Chong-Kwan (East-West Cancer Center, Dunsan Oriental Hospital of Daejeon Universuty) ;
  • Lee, Yeon-Weol (East-West Cancer Center, Dunsan Oriental Hospital of Daejeon Universuty)
  • 박재우 (대전대학교 한의학과 동서암센터) ;
  • 유화승 (대전대학교 한의학과 동서암센터) ;
  • 조종관 (대전대학교 한의학과 동서암센터) ;
  • 이연월 (대전대학교 한의학과 동서암센터)
  • Received : 2011.11.16
  • Accepted : 2011.02.08
  • Published : 2011.02.20
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : To investigate the therapeutic effects of HangAm-Plus (HAP) on advanced gastric cancer patient. Methods : A 53 year old male patient diagnosed with advanced gastric cancer (T3N3M1) was admitted to EWCC (East-West Cancer Center) on Nov. 20008. He had refused to go through the standard cancer regimen after having total gastrectomy on Jul 2008. The patient was treated with HAP (3,000 mg/day) for the period of 11 months from Nov 27th, 2008 to Oct 10th, 2009. Computed tomography (CT) and endoscopy were used to evaluate the disease progression of the patient. Results : HAP treatment was well tolerated by the patient. Patient has shown 25 months of stable disease condition up until now. Conclusion : This case study supports HAP's potential efficacy in treating advanced gastric cancer patients.

Keywords

References

  1. Shin HR, Won YJ, Jung KW, Park JG. 2001 Annual report of the Korea Central Cancer Registry : Base on registered data from 134 hospitals. Cancer Res Treat, 36(1):19-30, 2004. https://doi.org/10.4143/crt.2004.36.1.19
  2. Ministry of Health & Welfare. Cancer Facts & Figures 2010. National Cancer Center, 2010.
  3. Ministry of Health and Welfare, Republic of Korea. Annual Report of the Korea Central Cancer Registry, 2008.
  4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8(2):163-168, 1997. https://doi.org/10.1023/A:1008243606668
  5. Kim JP. Current status of surgical treatment of gastric cancer. J Surg Oncol, 79(2):79-80, 2002. https://doi.org/10.1002/jso.10050
  6. Hur H, Park CH. Surgical treatment of gastric carcinoma. Korean J Gastroenterol, 54(2):83-98, 2009. https://doi.org/10.4166/kjg.2009.54.2.83
  7. Ajani JA, Fordor MB, Tjulandin SA, Moiseynko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of doxetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol, 23(24):5660-5667, 2005. https://doi.org/10.1200/JCO.2005.17.376
  8. Yoo HS, Lee YY, Song KC, Choi BL, Seo SH, Cho JH, et al. The effects of HangAmDan(HAD) on anti-metastasis and preventing relapses, administered to 69 cancer patients. Korean J.Orient. Int. Med, 23(2):165-173, 2002.
  9. Park JS, Yoo HS, Lee YW, Cho JH, Son CG, Cho CK. Wheel Balance Cancer Therapy in the treatment of metastatic gastric carcinoma : A retrospective analysis of 62 patients. Korean J. Orient. Int. Med, 28(3):531-543, 2007.
  10. Lee DE, Lee SY, Kim JS, Cho CK, Yoo HS, Choi SJ. Antitumor effect of Hang-Am-Dan (HAD) and its ingredients on Calu6 and MCF-7 human cacner cell lines. J Kor. Oriental Med, 30(5):50-60, 2009.
  11. Bang JY, Kim EY, Shim TK, Yoo HS, Lee YW, Kim YS, Cho CK et al. Analysis of anti-angiogenic mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine, using antibody microarray chip. BioChip J, 4(4):350-355, 2010. https://doi.org/10.1007/s13206-010-4412-5
  12. Lee HJ, Kim JS, Yoon JW, Lee YW, Cho CK, Yoo HS, et al. Toxicological study on HangAmDan-B in Mice. JAMS, in press, 2011.
  13. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, et al. Elevated levels of curculating platelet microparticles, VEGF, IL6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer, 39(2):184-191, 2003. https://doi.org/10.1016/S0959-8049(02)00596-8
  14. Lee NH, Yoon DH, Yoo HS, Cho JH, Lee YW, Cho CK, et al. Changes of serum VEGF, bFGF levels and platelet counts in 100 cancer patients treated with Hang-Am-Dan. Korean J. Orient. Int. Med, 26(4):753-760, 2005.
  15. Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, et al. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-$\beta$ phosphorylation, and microvessel density in gastric cancer. BMC Cancer, 30(10):659-669, 2010.
  16. M. Klagsburn, Mediators of angiogenesis: the biological ignificance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions, Semin Cancer Biol, 3(2):81-87, 1992.